Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial.
暂无分享,去创建一个
M. Puhan | M. Seeberger | M. Schläpfer | B. Beck-Schimmer | K. Dedes | D. Fink | C. Tausch | C. Dumrese | B. Papassotiropoulos | B. R. Z'graggen | J. Braun | C. Ewald | F. Hovaguimian | U. Rölli | B. R. Z’graggen
[1] E. Mascha,et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial , 2019, The Lancet.
[2] W. Han,et al. Total Intravenous Anesthesia versus Inhalation Anesthesia for Breast Cancer Surgery: A Retrospective Cohort Study , 2019, Anesthesiology.
[3] A. Gavin,et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.
[4] Yue-Cune Chang,et al. Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery , 2018, Anesthesiology.
[5] A. Schneeweiss,et al. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer , 2018, Breast Cancer Research and Treatment.
[6] Tao Yan,et al. Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-β and prognosis after breast cancer surgery: a prospective, randomized and controlled study , 2018, BMC Anesthesiology.
[7] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[8] S. Sleijfer,et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis , 2018, Journal of the National Cancer Institute.
[9] T. Oh,et al. Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery , 2018, Cancer control : journal of the Moffitt Cancer Center.
[10] E. Sloan,et al. Perioperative events influence cancer recurrence risk after surgery , 2018, Nature Reviews Clinical Oncology.
[11] Guonian Wang,et al. Effects of propofol-based total intravenous anesthesia on gastric cancer: a retrospective study , 2018, OncoTargets and therapy.
[12] P. Ferrari,et al. Prognostic and predictive biomarkers in breast cancer: Past, present and future. , 2017, Seminars in cancer biology.
[13] Daniel F. Hayes,et al. 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.
[14] Leonie L. Zeune,et al. Quantifying HER-2 expression on circulating tumor cells by ACCEPT , 2017, PloS one.
[15] H. Kim,et al. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study , 2017, Scientific Reports.
[16] J. Soria,et al. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. , 2017, European journal of cancer.
[17] J. H. Lee,et al. The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: A Prospective Randomized Study , 2017, International journal of medical sciences.
[18] M. Hollmann,et al. Perioperative Anesthesia Care and Tumor Progression , 2017, Anesthesia and analgesia.
[19] A. Tsung,et al. Surgery for Cancer: A Trigger for Metastases. , 2017, Cancer research.
[20] F. Bidard,et al. Circulating tumor cells: clinical validity and utility , 2017, International Journal of Clinical Oncology.
[21] Bongseog Kim,et al. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study , 2016, Korean journal of anesthesiology.
[22] Kabir Mohammed,et al. Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis , 2016, Anesthesiology.
[23] J. Orange,et al. Practical NK cell phenotyping and variability in healthy adults , 2015, Immunologic Research.
[24] V. Servois,et al. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. , 2015, Cancer letters.
[25] L. Bergkvist,et al. The choice of anaesthetic—sevoflurane or propofol—and outcome from cancer surgery: A retrospective analysis , 2014, Upsala journal of medical sciences.
[26] Andreas Trumpp,et al. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients , 2014, BMC Cancer.
[27] Tanja Fehm,et al. Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.
[28] T. Fehm,et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.
[29] P. Doran,et al. Propofol and bupivacaine in breast cancer cell function in vitro - role of the NET1 gene. , 2014, Anticancer research.
[30] T. Song,et al. Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460 , 2014, Tumor Biology.
[31] Yan-bing Xu,et al. Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity. , 2013, World journal of gastroenterology.
[32] Jing Chen,et al. Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. , 2013, European review for medical and pharmacological sciences.
[33] M. Gallucci,et al. Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical Cystectomy: preliminary results , 2013, Journal of experimental & clinical cancer research : CR.
[34] B. Faltas. Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells , 2012, Front. Oncol..
[35] Massimo Cristofanilli,et al. Considerations in the development of circulating tumor cell technology for clinical use , 2012, Journal of Translational Medicine.
[36] J. Lewis,et al. Evaluation of a Flow Cytometry‐Based Assay for Natural Killer Cell Activity in Clinical Settings , 2012, Scandinavian journal of immunology.
[37] Qingxiu Wang,et al. Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[38] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[39] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[40] D. Moher,et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. , 2012, International journal of surgery.
[41] Stefan Sleijfer,et al. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. , 2009, Cancer treatment reviews.
[42] Mieke Schutte,et al. Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.
[43] G. Sauter,et al. High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.
[44] M. Gail,et al. The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.
[45] A. Schatzkin. Intermediate markers as surrogate endpoints in cancer research. , 2000, Hematology/oncology clinics of North America.
[46] D. Hedeker,et al. Sample Size Estimation for Longitudinal Designs with Attrition: Comparing Time-Related Contrasts Between Two Groups , 1999 .
[47] J. Schmitz,et al. Determination of natural killer cell function by flow cytometry , 1996, Clinical and diagnostic laboratory immunology.